Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Int J Med Sci 2013; 10(8):1015-1021. doi:10.7150/ijms.6402 This issue Cite

Research Paper

Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment

Masato Nakamura1, Tatsuo Kanda1, ✉, Tatsuo Miyamura1, Shuang Wu1, Shingo Nakamoto1,2, Osamu Yokosuka1

1. Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan;
2. Department of Molecular Virology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.

✉ Corresponding author: Tatsuo Kanda, M.D., Ph.D., Associate Professor, Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba (260-8670), Japan. Tel.: +81-43-226-2086, Fax: +81-43-2 More

Citation:
Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O. Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment. Int J Med Sci 2013; 10(8):1015-1021. doi:10.7150/ijms.6402. https://www.medsci.org/v10p1015.htm
Other styles

File import instruction

Abstract

Alanine aminotransferase (ALT) elevation was occassionally observed during the treatment with combination peginterferon alpha plus ribavirin. Two forms of peginterferon are currently available as a standard of care with or without direct-acting antivirals against hepatitis C virus (HCV). Until the appearance of interferon-sparing regimen, peginterferon alpha plus ribavirin will play a central role in the eradication of HCV. In the present study, we compared ALT elevations in response to peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin in HCV genotype-1-infected patients. There were no significant differences in ALT elevations between treatments with the two peginterferons, but in a comparison of the proportions of patients with transient ALT elevation from baseline between the two groups, transient ALT elevation was observed more in sustained virological response (SVR) patients treated with peginterferon alpha-2a than with peginterferon alpha-2b. However, no patients discontinued treatment due to ALT elevation. Patients with transient ALT elevation from baseline during the treatment had less favorable IL28B rs8099917 genotype in the peginterferon alpha-2b group. Patients achieving SVR tended to have lower ALT levels, although some had persistent ALT elevation during treatment. In conclusion, clinicians should pay attention to possible ALT elevation during the treatment of chronic hepatitis C patients.

Keywords: ALT, HCV, IL28B, Peginterferon, Ribavirin.

Citation styles

APA
Nakamura, M., Kanda, T., Miyamura, T., Wu, S., Nakamoto, S., Yokosuka, O. (2013). Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment. International Journal of Medical Sciences, 10(8), 1015-1021. https://doi.org/10.7150/ijms.6402.

ACS
Nakamura, M.; Kanda, T.; Miyamura, T.; Wu, S.; Nakamoto, S.; Yokosuka, O. Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment. Int. J. Med. Sci. 2013, 10 (8), 1015-1021. DOI: 10.7150/ijms.6402.

NLM
Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O. Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment. Int J Med Sci 2013; 10(8):1015-1021. doi:10.7150/ijms.6402. https://www.medsci.org/v10p1015.htm

CSE
Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, Yokosuka O. 2013. Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment. Int J Med Sci. 10(8):1015-1021.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use